Time to optimize vaccination strategies in blood cancer patients-Reference-Cited by-同舟云学术

Time to optimize vaccination strategies in blood cancer patients

Published:2024-06-19 Issue:2 Volume:205 Page:406-408
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Muhsen Ibrahim N.¹^ORCID,Heslop Helen E.¹²^ORCID

Affiliation:

1. Dan L. Duncan Comprehensive Cancer Center Baylor College of Medicine Houston Texas USA

2. Center for Cell and Gene Therapy, Baylor College of Medicine Texas Children's Hospital, Houston Methodist Hospital Houston Texas USA

Abstract

Immune response to vaccinations is dampened in patients with indolent lymphomas due to disease and treatment‐related factors. The study by Lim et al. demonstrated impaired humoral response but intact cellular response to the SARS‐CoV2 vaccine in patients with follicular lymphoma receiving front‐line therapy. The results highlight the importance of several factors in predicting immune response to vaccination and provide estimates of immune response for different clinical scenarios and treatment points.Commentary on: Lim et al. Immunogenicity of COVID‐19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy. Br J Haematol 2024;205:440‐451.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.19598

Reference10 articles.

1. Immunogenicity of COVID‐19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy

2. T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study

3. Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study

4. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma

5. Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies